Inclusion Criteria:

- informed consent, histological diagnosis of persistent, recurrent or metastatic
cervical carcinoma; measurable disease by physical examination, CT Scan, MRI or
PET-CT. Biopsy is required for confirmation only if the lesion is unique, has less
than 2cm in the longest diameter or has no clearly defined borders.

- Patients should have no previous systemic treatment (could have received chemotherapy
as radiosensitization to the pelvis and or para-aortic field.

- Aged >18 years, performance status 0-2 according to ECOG classification, and adequate
liver, hematological and renal function, as defined by: hemoglobin >10 g/L,
leukocytes >4000/mm3, platelets >100 000mm3; normal creatinine value and creatinine
clearance >60 mL/min; total bilirubin < 1.5 upper normal limit value.

Exclusion Criteria:

- History of allergy to hydralazine or valproate; past or present condition of
rheumatic disease, central nervous system disease, heart failure from aortic stenosis
and postural hypotension as diagnosed by a physician; newly diagnosed hypertension
patients with or without pharmacological treatment are allowed as long as their
treatment do not include hydralazine.

- Previous use of the experimental drugs (hydralazine and magnesium valproate) as well
as if patients were pregnant or breast-feeding. Other exclusion criteria are
uncontrolled systemic disease or infection.